NextGen Biomed (XTAE:NXGN) Change In Inventory : ₪0.00 Mil (TTM As of Jun. 2023)

View and export this data going back to 2000. Start your Free Trial

What is NextGen Biomed Change In Inventory?

NextGen Biomed's change in inventory for the quarter that ended in Jun. 2023 was ₪0.00 Mil. It means NextGen Biomed's inventory stayed the same from Dec. 2022 to Jun. 2023 .

NextGen Biomed's change in inventory for the fiscal year that ended in Dec. 2022 was ₪0.00 Mil. It means NextGen Biomed's inventory stayed the same from Dec. 2021 to Dec. 2022 .

NextGen Biomed's Total Inventories for the quarter that ended in Jun. 2023 was ₪0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

NextGen Biomed Change In Inventory Historical Data

The historical data trend for NextGen Biomed's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NextGen Biomed Change In Inventory Chart

NextGen Biomed Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Change In Inventory

Get a 7-Day Free Trial

NextGen Biomed Semi-Annual Data
	Dec13	Dec14	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Change In Inventory	Get a 7-Day Free Trial													-	-	-	-	-

NextGen Biomed Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₪0.00 Mil.

NextGen Biomed (XTAE:NXGN) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

NextGen Biomed's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0	/	0	*	365 / 2
	=	N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

NextGen Biomed's Inventory Turnover for the quarter that ended in Jun. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=	N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

NextGen Biomed's Inventory to Revenue for the quarter that ended in Jun. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	0
	=	N/A

NextGen Biomed Change In Inventory Related Terms

Thank you for viewing the detailed overview of NextGen Biomed's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

NextGen Biomed (XTAE:NXGN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NextGen Biomed Ltd (XTAE:NXGN) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

N/A

Address

Azrieli Center, Round Tower 22nd Floor, Tel Aviv, ISR, 6701101

Website

http://www.nextgen-biomed.com

NextGen Biomed Ltd is pharmaceutical company. It manufactures medical instruments. Its products include pain-free auto-injectors, lancet devices and personal use pain alleviators. It develops and markets medical equipments. Its product line include DPS-101, which is used for treatment for psoriasis. Its other product line include DPS-101 phase II/III is in clinical trial.